• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

基线阿南达胺水平和体重影响雄性大鼠中CB1受体拮抗作用的体重减轻效果。

Baseline anandamide levels and body weight impact the weight loss effect of CB1 receptor antagonism in male rats.

作者信息

Karlsson Cecilia, Hjorth Stephan, Karpefors Martin, Hansson Göran I, Carlsson Björn

机构信息

CVMD Translational Medicine Unit, Early Clinical Development (C.K., B.C.), CVMD Bioscience (S.H.), and CVMD Translational Sciences (G.I.H.), Innovative Medicines, and Biomedical Informatics (M.K.), Advanced Analytics Centre, AstraZeneca R&D, SE-431 83, Mölndal, Sweden.

出版信息

Endocrinology. 2015 Apr;156(4):1237-41. doi: 10.1210/en.2014-1730. Epub 2014 Dec 30.

DOI:10.1210/en.2014-1730
PMID:25549047
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4399312/
Abstract

The individual weight loss response to obesity treatment is diverse. Here we test the hypothesis that the weight loss response to the CB1 receptor antagonist rimonabant is influenced by endogenous levels of receptor agonists. We show that baseline anandamide levels and body weight independently contribute to predict the treatment response to rimonabant in rodents, demonstrating that addition of biomarkers related to mode of action is relevant for a personalized health care approach to obesity treatment.

摘要

个体对肥胖治疗的体重减轻反应各不相同。在此，我们检验了一种假说，即对CB1受体拮抗剂利莫那班的体重减轻反应受受体激动剂内源性水平的影响。我们发现，基线花生四烯乙醇胺水平和体重可独立预测啮齿动物对利莫那班的治疗反应，这表明添加与作用模式相关的生物标志物对于肥胖治疗的个性化医疗方法具有重要意义。

相似文献

1
Baseline anandamide levels and body weight impact the weight loss effect of CB1 receptor antagonism in male rats.基线阿南达胺水平和体重影响雄性大鼠中CB1受体拮抗作用的体重减轻效果。
Endocrinology. 2015 Apr;156(4):1237-41. doi: 10.1210/en.2014-1730. Epub 2014 Dec 30.
2
O-2050 facilitates noradrenaline release and increases the CB1 receptor inverse agonistic effect of rimonabant in the guinea pig hippocampus.O-2050促进去甲肾上腺素释放，并增强利莫那班在豚鼠海马体中的CB1受体反向激动作用。
Naunyn Schmiedebergs Arch Pharmacol. 2014 Jul;387(7):621-8. doi: 10.1007/s00210-014-0991-3. Epub 2014 May 23.
3
Anandamide transport inhibition by ARN272 attenuates nausea-induced behaviour in rats, and vomiting in shrews (Suncus murinus).ARN272对花生四烯乙醇胺转运的抑制作用可减轻大鼠的恶心诱导行为以及短尾鼩鼱（Suncus murinus）的呕吐行为。
Br J Pharmacol. 2013 Nov;170(5):1130-6. doi: 10.1111/bph.12360.
4
Anandamide attenuates haloperidol-induced vacuous chewing movements in rats.花生四烯乙醇胺可减轻氟哌啶醇诱导的大鼠空嚼运动。
Prog Neuropsychopharmacol Biol Psychiatry. 2014 Oct 3;54:195-9. doi: 10.1016/j.pnpbp.2014.04.006. Epub 2014 Apr 18.
5
ENP11, a potential CB1R antagonist, induces anorexia in rats.
Pharmacol Biochem Behav. 2015 Aug;135:177-81. doi: 10.1016/j.pbb.2015.06.007. Epub 2015 Jun 11.
6
Anandamide activation of CB1 receptors increases spontaneous bursting and oscillatory activity in the thalamus.花生四烯乙醇胺对CB1受体的激活会增加丘脑的自发放电和振荡活动。
Neuroscience. 2014 Apr 18;265:72-82. doi: 10.1016/j.neuroscience.2014.01.049. Epub 2014 Feb 5.
7
The endocannabinoid system: a new target for the regulation of energy balance and metabolism.内源性大麻素系统：调节能量平衡和新陈代谢的新靶点。
Crit Pathw Cardiol. 2007 Jun;6(2):46-50. doi: 10.1097/HPC.0b013e318057d4b4.
8
Microinjection of 2-arachidonoyl glycerol into the rat ventral hippocampus differentially modulates contextually induced fear, depending on a persistent pain state.向大鼠腹侧海马体中微注射 2-花生四烯酸甘油，可根据持续性疼痛状态，有差异地调节情境诱导的恐惧。
Eur J Neurosci. 2014 Feb;39(3):435-43. doi: 10.1111/ejn.12452.
9
The cannabinoid CB1 receptor antagonist SR141716A (Rimonabant) enhances the metabolic benefits of long-term treatment with oleoylethanolamide in Zucker rats.大麻素CB1受体拮抗剂SR141716A（利莫那班）可增强油酸乙醇酰胺对 Zucker 大鼠长期治疗的代谢益处。
Neuropharmacology. 2008 Jan;54(1):226-34. doi: 10.1016/j.neuropharm.2007.03.007. Epub 2007 Mar 24.
10
Acute effects of endocannabinoid anandamide and CB1 receptor antagonist, AM251 in the regulation of thyrotropin secretion.内源性大麻素花生四烯酸乙醇胺和CB1受体拮抗剂AM251对促甲状腺激素分泌调节的急性影响。
J Endocrinol. 2008 Nov;199(2):235-42. doi: 10.1677/JOE-08-0380. Epub 2008 Aug 28.

引用本文的文献

1
Targeting the Endocannabinoid CB1 Receptor to Treat Body Weight Disorders: A Preclinical and Clinical Review of the Therapeutic Potential of Past and Present CB1 Drugs.靶向内源性大麻素 CB1 受体治疗体重紊乱：过去和现在 CB1 药物治疗潜力的临床前和临床综述。
Biomolecules. 2020 Jun 4;10(6):855. doi: 10.3390/biom10060855.

本文引用的文献

1
The endocannabinoid system in energy homeostasis and the etiopathology of metabolic disorders.内源性大麻素系统在能量平衡和代谢紊乱的发病机制中的作用。
Cell Metab. 2013 Apr 2;17(4):475-90. doi: 10.1016/j.cmet.2013.03.001.
2
Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme.利拉鲁肽与对照药物治疗的体重变化：来自利拉鲁肽糖尿病研发项目的 7 项 3 期临床试验分析。
Diabetes Obes Metab. 2013 Jan;15(1):42-54. doi: 10.1111/j.1463-1326.2012.01673.x. Epub 2012 Sep 9.
3
Prediction of weight loss and regain following dietary, lifestyle, and pharmacologic intervention.饮食、生活方式和药物干预后体重减轻和反弹的预测。
Clin Pharmacol Ther. 2012 Jun;91(6):1027-34. doi: 10.1038/clpt.2011.333. Epub 2012 Feb 15.
4
Quantification of endocannabinoids in biological systems by chromatography and mass spectrometry: a comprehensive review from an analytical and biological perspective.通过色谱法和质谱法对生物系统中的内源性大麻素进行定量分析：从分析和生物学角度的全面综述
Biochim Biophys Acta. 2011 Nov;1811(11):706-23. doi: 10.1016/j.bbalip.2011.08.004. Epub 2011 Aug 19.
5
International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂.国际基础和临床药理学联合会. LXXIX. 大麻素受体及其配体：超越 CB₁ 和 CB₂。
Pharmacol Rev. 2010 Dec;62(4):588-631. doi: 10.1124/pr.110.003004.
6
Role of acylethanolamides in the gastrointestinal tract with special reference to food intake and energy balance.酰基乙醇酰胺在胃肠道中的作用，特别涉及食物摄入和能量平衡。
Best Pract Res Clin Endocrinol Metab. 2009 Feb;23(1):33-49. doi: 10.1016/j.beem.2008.10.003.
7
Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program.利莫那班改善超重/肥胖患者多种心血管代谢危险因素的疗效和安全性：来自肥胖症利莫那班（RIO）项目的1年汇总数据。
Diabetes Care. 2008 Feb;31 Suppl 2:S229-40. doi: 10.2337/dc08-s258.
8
The cannabinoid CB1 receptor inverse agonist, rimonabant, modifies body weight and adiponectin function in diet-induced obese rats as a consequence of reduced food intake.大麻素CB1受体反向激动剂利莫那班，因食物摄入量减少，可改变饮食诱导肥胖大鼠的体重和脂联素功能。
Pharmacol Biochem Behav. 2006 Jun;84(2):353-9. doi: 10.1016/j.pbb.2006.06.001. Epub 2006 Jun 30.
9
Release of anandamide from blood cells.花生四烯乙醇胺从血细胞中的释放。
Clin Chem Lab Med. 2006;44(4):488-91. doi: 10.1515/CCLM.2006.065.
10
Predictors of weight loss in adults with topiramate-treated epilepsy.托吡酯治疗的成人癫痫患者体重减轻的预测因素。
Obes Res. 2003 Apr;11(4):556-62. doi: 10.1038/oby.2003.78.